{"name":"Aramis Biosciences, Inc.","slug":"aramis-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"A197 Ophthalmic Solution","genericName":"A197 Ophthalmic Solution","slug":"a197-ophthalmic-solution","indication":"Treatment of inflammation and pain in the eye","status":"phase_2"}]}],"pipeline":[{"name":"A197 Ophthalmic Solution","genericName":"A197 Ophthalmic Solution","slug":"a197-ophthalmic-solution","phase":"phase_2","mechanism":"A197 Ophthalmic Solution is a topical corticosteroid used to reduce inflammation in the eye.","indications":["Treatment of inflammation and pain in the eye"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNUzN1MEE0NTlVbzNzYkRsc2ZNVXFjX002SEpKcW91U3gzNGRrRVdyakd2bjBVbWlUSjVrTkZPekxuOERHeWt4dEwxNVR4YzZkamZiY21td2N3b2RNdWNNeVNNcjV3ZmliWlJ1ZmNwMTBudmktaUI0RkJzekpxa3QwY2t0all1Si1LZ2FNN21ZcTZuNFBwZWhfSld0cjA4MEVMdktmQ1FTM3ZrM2V5cFVMbDdwVTFQY01yWjZkX04yNnlRVTVxbXlKLTd3MHNXc2habEp0TTNYcXpuaG42SkJMcmVtaHNxUmt3RVdQbTZDNGQwUjR6LWVWN0NvbEpvenlkWk5ZWXp3?oc=5","date":"2026-03-12","type":"trial","source":"StreetInsider","summary":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - StreetInsider","headline":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"PR Newswire","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - PR Newswire","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQdmV0cFhHWlpkaWtsMFlPajRJVk5nMTFvaWZYSG13d0w5MWd2SWJQWlNrWWRQNjZvUTF4NnBCOTJqcWdMdUd1VFdQbmdFYWZFMVNBRWJvV2NRRktKU0hYb0s1UGlPTE1vN1dGaDhHTVdPRnUybHhtRmtKd3F4WHYtXzN4ZmJ6SzdUN0NXREVvUDBVS29YT0RvSEx1SHlESXRza21WRlBDUFBXWER0enVoOWFqTXBNck5TNlpvNjBkUG9WYlFvNVRUUVMzWDJ0bUxIa1dkQVJoQ3kyTG8?oc=5","date":"2021-12-15","type":"pipeline","source":"globenewswire.com","summary":"Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology - globenewswire.com","headline":"Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}